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Lipopolysaccharide-Induced Expression of
Multiple Alternatively Spliced MEFV Transcripts in
Human Synovial Fibroblasts
A Prominent Splice Isoform Lacks the C-Terminal Domain That Is Highly
Mutated in Familial Mediterranean Fever
Arturo Diaz,1 Chunbo Hu,1 Daniel L. Kastner,2 Philip Schaner,1 Anthony M. Reginato,3
Neil Richards,1 and Deborah L. Gumucio1
Objective. To investigate the expression of the
familial Mediterranean fever (FMF) gene (MEFV) in
human synovial fibroblasts.
Methods. MEFV messenger RNA in synovial fi-
broblasts, chondrocytes, and peripheral blood leuko-
cytes (PBLs) was analyzed by semiquantitative and
real-time polymerase chain reaction and ribonuclease
protection assay. The subcellular localization of pyrin,
the MEFV product, was determined in transfected syno-
vial fibroblasts and HeLa cells with plasmids encoding
pyrin isoforms. Native pyrin was detected with an
antipyrin antibody.
Results. MEFV was expressed in synovial fibro-
blasts, but not in chondrocytes. Four alternatively
spliced transcripts were identified: an extension of exon
8 (exon 8ext) resulting in a frameshift that predicts a
truncated protein lacking exons 9 and 10, the addition of
an exon (exon 4a) predicting a truncated protein at exon
5, the in-frame substitution of exon 2a for exon 2, and
the previously described removal of exon 2 (exon 2).
Exon 8ext transcripts represented 27% of the total
message population in synovial fibroblasts. All other
alternatively spliced transcripts were rare. Consensus
and alternatively spliced transcripts were induced by
lipopolysaccharide in synovial fibroblasts and PBLs. In
transfected cells, the proteins encoded by all highly
expressed splice forms were cytoplasmic. In contrast,
native pyrin was predominantly nuclear in synovial
fibroblasts, neutrophils, and dendritic cells, but was
cytoplasmic in monocytes.
Conclusion. Several MEFV transcripts are ex-
pressed and inducible in synovial fibroblasts. A promi-
nent isoform lacks the C-terminal domain that contains
the majority of mutations found in patients with FMF.
While recombinant forms of all major pyrin isoforms
are cytoplasmic, native pyrin is nuclear in several cell
types. Thus, mechanisms in addition to splicing pat-
terns must control pyrin’s subcellular distribution.
Familial Mediterranean fever (FMF) (MIM no.
249100) is the most common of a newly recognized
group of diseases characterized by recurrent episodes of
inflammation. Because of the lack of an apparent trigger
and of a specific immune response, these conditions are
defined as autoinflammatory syndromes (1,2). In the
recent past, molecular approaches have identified gene
mutations that have helped to better define many of
these conditions, including FMF, tumor necrosis factor
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receptor–associated periodic syndrome (TRAPS) (3),
familial cold urticaria (FCU) (4), Muckle-Wells syn-
drome (MWS) (5), neonatal-onset multisystem inflam-
matory disease/chronic infantile neurologic, cutaneous,
articular syndrome (NOMID/CINCA syndrome), (6),
hyperimmunoglobulinemia D with periodic fever syn-
drome (HIDS) (7,8), pyogenic sterile arthritis, pyo-
derma gangrenosum and arthritis syndrome (PAPA
syndrome) (9), and Blau syndrome (10).
FMF is an autosomal-recessive disease that is
prevalent in the Mediterranean basin, affecting people
of Jewish, Armenian, Turkish, and Arab ancestry. It is
characterized by apparently spontaneous and recurrent
episodes of fever and painful serosal inflammation in-
volving the pleura, pericardium, peritoneum, and syno-
vium; other tissues may be affected less frequently. The
arthritis of FMF is characterized by episodes of acute
monarthritis, although rarely, patients will develop a
chronic arthropathy with osteopenia and bone erosions.
During the attacks, there is elevation of the leukocyte
count, erythrocyte sedimentation rate, and acute-phase
reactant levels; the leukocyte count in the synovial fluid
can reach values as high as 1,000,000/mm3. The most
significant late complication of FMF is amyloidosis,
which results in chronic renal insufficiency (11,12).
MEFV was cloned in 1997 (13,14). It spans a
15-kb interval on chromosome 16p, contains 10 exons
that comprise a 3. 7-kb transcript, and encodes a 781–
amino acid protein named pyrin (13) or marenostrin
(14), hereinafter referred to as pyrin. Pyrin contains
several identifiable domains: a pyrin domain at the
N-terminus, a bZIP transcription factor basic domain, a
B box–type zinc finger, 2 putative nuclear localization
signals, a coiled-coil domain, and a C-terminal domain
known as a B30.2, rfp, or SPRY domain. Approximately
40 mutations have been identified in FMF patients, most
of them localized in the B30.2/rfp/SPRY domain. Pyrin
is the founding member of a growing family of proteins
containing a pyrin domain (also known as DAPIN,
PAAD, or PYD) (15–17), a death domain–like structure
known to interact with other pyrin domain–containing
proteins, such as ASC, that are involved in the regulation
of apoptosis and NF-B activation (18). Pyrin has also
been shown to interact with PSTPIP1/CD2BP1, the
protein mutated in PAPA syndrome, providing a link
between the actin cytoskeleton, protein phosphoryla-
tion, and the inflammatory process (9,19).
Although the role of pyrin in inflammation has
not been elucidated, the fact that mutations are associ-
ated with spontaneous inflammatory attacks indicates
that the protein is a relevant regulator of the inflamma-
tory process. The mechanisms that trigger FMF attacks
and the underlying reasons for the localization of the
ensuing inflammation have yet to be established. Human
MEFV messenger RNA (mRNA) is expressed in poly-
morphonuclear cells (PMNs), eosinophils, and mono-
cytes, but absent from lymphocytes (13,14,20). It is
possible that FMF attacks reflect abnormal trafficking of
PMNs or altered chemotactic signaling from monocyte/
macrophages. However, structural cells at the site of the
targeted inflammation could also be involved in attack
localization. Matzner et al (21) showed that pyrin is
indeed expressed in skin and peritoneal fibroblasts.
Although early studies indicated that MEFV mRNA
could also be amplified from synovium by reverse
transcriptase–polymerase chain reaction (RT-PCR)
(14), the regulation of the MEFV transcript and pyrin
protein in this tissue has not been previously analyzed.
In the present study we investigated the expres-
sion of MEFV in human synovial fibroblasts treated with
the proinflammatory stimulus lipopolysaccharide (LPS)
and determined the subcellular localization of the re-
combinant and native pyrin proteins. Our data demon-
strate that pyrin is expressed and inducible in the
synovium, an important target site of FMF attacks. We
identified transcripts with alternative splicing events at
exon 2, exon 4, and exon 8 in synovial fibroblasts and
peripheral blood leukocytes (PBLs); only the latter was
expressed at significant levels. We found that in trans-
fected synovial fibroblasts, full-length pyrin protein has a
cytoplasmic localization, as do all but 1 of the predicted
protein isoforms; only the rare isoform encoded by
transcripts lacking exon 2 was occasionally nuclear.
However, native pyrin had a predominantly nuclear
localization in synovial fibroblasts, PMNs, and dendritic
cells (DCs), although it was cytoplasmic in monocytes.
These findings imply previously unrecognized complex-
ity in the posttranscriptional processing of MEFV.
MATERIALS AND METHODS
Cell culture. Primary human synovial fibroblasts (pas-
sages 4–10) were obtained from patients with osteoarthritis
(OA) as previously described (22) and cultured with Dulbec-
co’s modified Eagle’s medium (DMEM) supplemented with
heat-inactivated 10% human serum and 10% fetal bovine
serum (FBS), L-glutamine, and 1% (volume/volume) penicillin/
streptomycin. Unfractionated PBLs were obtained from
healthy volunteers (University of Michigan Institutional Re-
view Board nos. 2000-0789 and 2000-0784) who were not
taking any drugs. PBLs were separated in Ficoll gradients
(Histopaque 1077; Sigma, St. Louis, MO). Unfractionated
PBLs were cultured under nonadherent conditions in poly-
HEME (Sigma)–covered 100-mm culture dishes, in 10% heat-
inactivated FBS. In some experiments, PMNs and monocytes
were enriched by Ficoll gradient or cell adhesion. Synovial
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fibroblasts and PBLs were incubated for various amounts of
time in the presence or absence of various concentrations of
LPS (from Escherichia coli serotype O127:B8; Sigma). Chon-
drocytes were obtained from human adult OA cartilage,
cultured as previously described (23), and incubated for 24
hours with LPS (30 ng/ml), interleukin-1 (IL-1; 1 ng/ml), or
tumor necrosis factor  (TNF; 5 ng/ml) (R&D Systems,
Minneapolis, MN). Human umbilical vein endothelial cells
(HUVECs) were cultured as described (24) and incubated for
24 hours with TNF (5 ng/ml). HeLa cells (American Type
Culture Collection, Rockville, MD) were cultured in DMEM
supplemented with 10% heat-inactivated FBS. Monocyte-
derived immature DCs were prepared as previously described
(25).
RNA isolation and RT-PCR. Cells were lysed in
TRIzol reagent (Invitrogen, Carlsbad, CA), and total RNA
was isolated and reverse transcribed with Superscript II RNase
H reverse transcriptase (Invitrogen). The complementary
DNA (cDNA) obtained was amplified by PCR using Taq DNA
polymerase (Invitrogen) with 32P-dCTP labeling. For am-
plification of the MEFV cDNA, a forward primer anchored
in exon 5 (5-GAACAGCAGGAGCATTTCTTTG) and a
reverse primer anchored in exon 10 (5-TGGTACTAC-
TTTTCCTTCATC) were used. PCR products were cloned
in the pCR 2.1-TOPO vector (Invitrogen) and sequenced.
MEFV cDNA containing only the consensus splicing of
exons 8/9 or the alternative exon 8ext were amplified using
a forward primer anchored in exon 5 (5-GAACAGCAG-
GAGCATTTCTTTG) and a reverse primer anchored at the
junction of exons 8/9 (5-AGCTCTGGAACATTGAACATT)
or in the extended region of exon 8 (5-CAAGTCAAC-
AGCACAAGGGA). MEFV cDNA containing exon 2 or
exon 2 was amplified using a forward primer anchored in
exon 2 (5-AGAAATTCTCCTGACTCTAG) or a primer
anchored at the splice junction of exons 1/3 (5-AGCCAT-
TCAGGGAAGGCCAC) and a reverse primer anchored in
exon 5 (5-ACAAAGAAATGCTCCTGCTGTTC). To assess
the equality of template loading, 18S RNA was amplified using
a 1:9 mixture of primers:competimers (QuantumRNA Univer-
sal 18S Standards; Ambion, Austin, TX). PCR conditions were
as follows: 94oC for 1 minute, 62oC for 30 seconds, and 72oC
for 30 seconds. PCR products were resolved in 4% nondena-
turing polyacrylamide gels and autoradiographed. For semi-
quantitative PCR, the linear phase of amplification was deter-
mined as previously described (26).
Real-time PCR. Reverse-transcribed RNA was di-
gested with RNase H and used as a template for real-time
PCR. Reactions were run in an I-Cycler (Sigma) using SYBR
Green as a reporter and Platinum Taq Polymerase (Invitro-
gen). PCR mixes contained 50 ng of cDNA (total RNA
equivalent); the annealing temperature and the MgCl con-
centration were optimized for each primer set. Each sample
was run in triplicate, and all runs were performed at least
twice. Primers were designed using the Beacon Designer 2.05
program (Premier Biosoft International, Palo Alto, CA). For
amplification of MEFV cDNA containing the consensus
exon 8/9 splicing, a 95-bp product was obtained with a forward
primer anchored in exon 7 (5-CTCCTCCACCAGAAG-
TCAG) and a reverse primer anchored at the splice junction of
exon 8/9 (5-AGCTCTGGAACATTGAACATT); the condi-
tions were as follows: 95oC for 2 minutes, and 40 cycles of 95oC
for 30 seconds, 53oC for 30 seconds, and 72oC for 10 seconds.
For amplification of MEFV cDNA containing the exon 8ext, a
158-bp product was obtained with a forward primer anchored
in exon 7 (5-CAAGTCAACAGCACAAGGGAACAC) and a
reverse primer anchored in the extended region of exon 8
(5-AGCTCTGGAACATTGAACATT); the conditions were
as follows: 95oC for 2 minutes, and 40 cycles of 95oC for 30
seconds, 58.4oC for 30 seconds, and 72oC for 10 seconds. To
normalize for template loading, reverse-transcribed 18S RNA
was amplified using a 1:9 primer:competimer mix; the condi-
tions were as follows: 95oC for 2 minutes, and 40 cycles of 95oC
for 30 seconds, 59.8oC for 30 seconds, and 72oC for 10 seconds.
Standard curves were generated using triplicates of
progressive 10-fold dilutions of plasmids containing the target
MEFV or 18S sequences, starting at 1012 mM DNA. The
dynamic range of the standard curves spanned 4 orders of
magnitude, with correlation coefficients of at least 0.95 and
efficiencies of at least 90%. Molar quantities of starting RNA
(cDNA equivalent) were calculated for MEFV splice variants
and for the corresponding 18S RNA for each sample. The
concentration of MEFV products was corrected by that of 18S
RNA, and the resulting values were expressed as arbitrary
units.
Plasmid construction. A cDNA spanning MEFV
exon 1 to exon 8ext was obtained by RT-PCR using a for-
ward primer anchored in exon 1 (5-ATGGCTAA-
GACCCCTAGTGAC) and a reverse primer anchored in the
exon 8ext (5-CTAAATAGGGCCCCTCAAGT) containing
5 Eco RI and 3 Xho I linkers. We obtained clones containing
exon 2a or exon 2. Constructs containing the desired splicing
combinations were derived from these 2 clones, a cDNA
containing exon 4a and the plasmid V75-1 containing a full-
length MEFV cDNA. Complementary DNA were excised from
the plasmids with Eco RI and Xho I, cut at a Kpn I site in exon
3, gel purified, and selected sequences ligated. All cDNA were
cloned in the plasmid pCMV–Tag 3A (Stratagene, La Jolla,
CA). A plasmid containing 18S sequences was prepared by
cloning the RT-PCR product obtained with the primer:
competimer mix, in the pCR 2.1-TOPO vector.
RNase protection assays. For analysis of exon 2 splic-
ing, a riboprobe was generated from a 5 linearized plasmid
containing 493 bp of MEFV coding sequences, from the ATG
(position 1) in exon 1 to the 472 position in exon 2 and cloned
in pCR2.1-TOPO plasmid. After hybridization and RNase
digestion, exon 2–containing transcripts resolve as a 493-bp
band and exon 2 transcripts as a 172-bp band. For analysis of
exon 8 splicing, a riboprobe was generated from a plasmid
containing MEFV coding sequences from the ATG (position 1)
to the stop codon in exon 8ext at position 1209. The plasmid
was linearized with Pst I at the junction of exons 5/6; this
generated a 255-bp probe. After hybridization and RNase
digestion, the product containing exon 8ext resolves as a
255-bp band and the product with the conventional exon 8/9
splicing runs as a 172-bp band. Riboprobes (-32P-UTP–
labeled) were prepared using the MaxiScript in vitro transcrip-
tion kit (Ambion). For RNase protection assays (RPAs), 30 g
of total RNA from synovial fibroblasts or 10 g of total RNA
from PBLs was used; RPAs were run at least twice, using the
RPA III kit (Ambion). Protected products were resolved by
polyacrylamide gel electrophoresis and autoradiographed.
Cellular transfection and protein localization. Syno-
vial fibroblasts were plated on type I collagen–covered glass
coverslips (Biocoat; Becton Dickinson, Bedford, MA), and
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HeLa cells on standard glass coverslips in 6-well plates. Plated
synovial fibroblasts were transfected with 3 g of DNA using
FuGENE reagent (Roche, Indianapolis, IN) or by the nucleo-
fection method using the Human Dermal Fibroblast Nucleo-
fector Kit (Amaxa Biosystems, Cologne, Germany), and then
plated. Twenty-four or 48 hours after transfection, cells were
fixed for 30 minutes in 4% paraformaldehyde in phosphate
buffered saline (PBS), permeabilized for 5 minutes with 0.5%
Triton X-100 in PBS, and blocked for 1 hour with 1% bovine
serum albumin, 10% goat serum in PBS–0.1% Tween. Primary
antibody was mouse monoclonal IgG anti-myc (9E10; Santa
Cruz Biotechnology, Santa Cruz, CA). Secondary antibody was
goat anti-mouse Alexa Fluor 568–conjugated polyclonal IgG
(Molecular Probes, Eugene OR). Cells were incubated for 1
hour with the primary and secondary antibodies diluted in
blocking solution. Nuclei were counterstained with 4,6-
diamidino-2-phenylindole (DAPI). Cells were visualized using
a Zeiss Axiophot 2 microscope or a Nikon Eclipse E800
microscope. For staining of native pyrin, the primary antibody
was a polyclonal rabbit antibody to human pyrin amino acids
1–374 (Ab93). The secondary antibody was a goat anti-rabbit
Alexa Fluor 568–conjugated polyclonal IgG (Molecular
Probes). Nuclei were counterstained with DAPI or Hoechst.
Cells were visualized as described above and with a Zeiss LMS
510 confocal microscope.
RESULTS
Expression of MEFV in synovial fibroblasts and
identification of an alternatively spliced transcript con-
taining an extension of exon 8. To survey MEFV expres-
sion in a variety of cell types found in the joint, we used
RT-PCR. MEFV message was not detected in chondro-
cytes incubated in medium alone or supplemented for 24
hours with LPS, TNF, or IL-1. Likewise, HUVECs
(untreated or incubated with TNF) did not express
MEFV transcripts. MEFV message was detected in DCs
and in synovial fibroblasts (Figure 1A); expression in
synovial fibroblasts was investigated further.
Semiquantitative RT-PCR of total RNA from
synovial fibroblasts, using primers anchored in exons 5
and 10, revealed a 680-bp amplicon, mildly inducible by
LPS. Sequencing confirmed that this band contained the
expected consensus spliced MEFV product. LPS stimu-
lation also caused a dose- and time-dependent stronger
induction of a transcript producing a larger (796-bp)
amplicon (Figure 1A). Induced transcripts were de-
tected as early as 2 hours. Sequencing of the larger PCR
product revealed that it contained an extension of exon
8 (exon 8ext), provided by the first 118 bp of intron 8.
This caused a frameshift resulting in multiple stop
codons, the first contained within the extension of exon
8, predicting a 613–amino acid truncated protein prod-
uct lacking exons 9 and 10 and thus missing the entire
rfp/SPRY/B30.2 domain (Figures 1B and C).
Semiquantitative RT-PCR using primers that
specifically detect only one splice form at a time con-
Figure 1. Expression of MEFV message in dendritic cells (DCs) and
synovial fibroblasts (SFs), and lipopolysaccharide (LPS) induction of an
alternatively spliced MEFV transcript containing an extension of exon 8 in
synovial fibroblasts. A, MEFV mRNA was analyzed by reverse
transcriptase–polymerase chain reaction (PCR) using primers anchored
in exons 5 and 10 (arrows in C); 18S RNA was amplified as control. PCR
products were labeled with 32P-dCTP and PCR was run for 27 cycles, a
point previously determined to be within the linear range of amplification
(data not shown). The expected 680-bp MEFV product is shown. Asterisk
indicates a larger induced product. Immature monocyte–derived DCs
were studied (left panel). Cultured synovial fibroblasts were incubated
with various concentrations of LPS for 24 hours (center panel), or with 30
ng/ml LPS for various amounts of time (right panel). B, Partial sequence
of the larger PCR product indicated by the asterisk in A. Characters in
boldface represent the first 118 bp from intron 8 (exon 8ext); this region
is flanked by sequences from exons 8 and 9. Underlined are the generated
3 stop codons within the extended region of exon 8 and exon 9. C,
Diagram of the MEFV gene (top); the introns are not drawn to scale.
Exons appear as numbered gray boxes, introns are represented by a black
line, and the extension of exon 8 (exon 8ext) is shown as a black box
adjacent to exon 8. Below are diagrams of the consensus (middle) and
alternatively (bottom) spliced mRNA and their predicted protein prod-
ucts, with the coding exons numbered. Several specific domains found in
the pyrin protein are aligned with their coding exons (P  pyrin domain;
Z  bZIP domain; B  B box domain; CC  coiled-coil domain; rfp 
rfp/B30.2/SPRY domain).
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firmed that LPS treatment induced both the consensus
and the alternatively spliced transcripts (Figure 2A) and
indicated that both transcripts were more abundant in
PBLs than in synovial fibroblasts. To demonstrate the
existence and estimate the relative abundance of tran-
scripts expressing exon 8ext by an independent tech-
nique not dependent on PCR, we performed RPA
(Figure 2B); transcripts containing exon 8ext were ex-
pressed at low levels in untreated PBLs and undetect-
able in untreated synovial fibroblasts. Treatment with
LPS induced exon 8ext–containing transcripts in both
cell populations, but these were less abundant than
consensus spliced transcripts.
Quantification of exon 8 splicing products by
real-time PCR. To quantify the effect of LPS on the
abundance of consensus and exon 8ext–containing tran-
scripts, we performed real-time PCR on synovial fibro-
blasts from 3 OA patients and PBLs from 3 healthy
subjects (Figure 2C). Untreated synovial fibroblasts ex-
pressed higher levels (2.6-fold) of consensus transcripts
than of alternatively spliced transcripts; treatment with
LPS resulted in a coordinated induction of both tran-
scripts (increased 3.8–fold). Exon 8ext transcripts repre-
sented 27% of the total (consensus plus alternatively
spliced) MEFV transcripts in both untreated and LPS-
treated synovial fibroblasts.
Untreated PBLs from the 3 unrelated healthy
donors contained widely different levels of MEFV tran-
scripts. Such individual variability was also documented
previously (20). As shown in Figure 2C, in all cases we
detected higher levels of consensus transcripts (average
15.7-fold) than of alternatively spliced transcripts. PBLs
incubated for 8 hours in medium alone displayed a
reduction in the expression of both transcripts (15.5-fold
for consensus and 9.5-fold for exon 8ext). This reduction
may reflect changes in the cellular environment under
tissue culture conditions and/or death of PMNs, known
MEFV-expressing cells. Treatment of PBLs with LPS for
8 hours resulted in increased induction of both tran-
scripts (4.1-fold for consensus, 4.7-fold for exon 8ext).
Although the transcript levels in total PBLs are some-
what “diluted” by the presence of lymphocytes, which do
not express pyrin, untreated PBLs incubated for 8 hours
expressed higher levels of both transcripts compared
with untreated synovial fibroblasts (22-fold for consen-
sus, 6-fold for exon 8ext). The exon 8ext–containing
transcripts represented a larger proportion of the total
message population in synovial fibroblasts (27%), how-
ever, than in PBLs (10%) (Figure 2C).
Splicing of exon 2. Papin et al previously identi-
fied an alternatively spliced transcript lacking exon 2 in
human PBLs (27). To test whether this exon 2 splice
form also occurs in synovial fibroblasts, total RNA from
synovial fibroblasts from 3 different individuals, and a
monocyte-enriched fraction of PBLs, were analyzed by
RT-PCR. LPS treatment of both cell types resulted in
Figure 2. LPS induction of consensus and exon 8ext–containing tran-
scripts in synovial fibroblasts and peripheral blood leukocytes (PBLs).
A, Cultured synovial fibroblasts (left) or freshly isolated unfractionated
PBLs (right) were incubated for 24 hours and 8 hours, respectively,
without (control [CNT]) or with LPS (30 ng/ml). Total RNA was
assayed for individual MEFV splice forms using a common forward
PCR primer anchored in exon 5. The reverse primer (RP) to detect
consensus spliced MEFV (Exon 8/9) spanned the splice junction of
exons 8 and 9 and produced a 350-bp product. The reverse primer
detecting exon 8ext–containing transcripts was located in the extended
region of exon 8 and produced a 408-bp product. PCR amplification
was carried out for 27 cycles in the presence of 32P-dCTP. B, RNase
protection assays. Left, An RNA probe containing sequences from
exon 6 to exon 8ext was used to generate protected RNA sequences of
172 bp from consensus spliced pyrin (Exon 6–8) and 255 bp from exon
8ext–containing transcripts (Exon 6–8ext). Right, Autoradiographs of
the products resolved by polyacrylamide gel electrophoresis. C, Real-
time PCR analysis of consensus and exon 8ext–containing transcripts
in synovial fibroblasts and PBLs. Synovial fibroblasts from 3 osteoar-
thritis patients were incubated without (control) or with LPS (30
ng/ml) for 24 hours and total RNA was obtained. Unfractionated PBLs
were prepared from 3 healthy donors, and total RNA was obtained at
time 0 or after 8 hours of incubation without or with LPS (30 ng/ml).
Real-time PCR analysis was performed as described in Materials and
Methods. Values are arbitrary units (AU) after normalization of
MEFV mRNA molar concentrations with 18S RNA molar concentra-
tions as described in Materials and Methods (mean and SD from the
3 synovial fibroblast donors and the 3 PBL donors) (values from
individual samples available at http://www.med.umich.edu/cdb/
sub_pages/People/gumucio.htm). See Figure 1 for other definitions.
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the induction of transcripts containing exon 2 (Figure
3A). Primers spanning the exon 1/3 junction were used
to detect transcripts lacking exon 2. This message was
detectable in monocytes and inducible with LPS. In
synovial fibroblasts, the exon 2 message was seen only
after LPS stimulation (Figure 3C). The rarity of the 2
message and the response to LPS was also demonstrated
by RPA (Figure 3C). Analysis by real-time PCR con-
Figure 3. Splicing of exon 2 in synovial fibroblasts and peripheral blood
leukocytes (PBLs). A, Cultured synovial fibroblasts from 3 subjects were
incubated for 24 hours without (control [CNT]) or with LPS (30 ng/ml).
Monocyte (Mo)–enriched PBLs from a healthy donor were incubated for
8 hours without or with LPS (30 ng/ml). Total RNA was used for reverse
transcriptase–PCR reactions, run for 35 cycles in the presence of 32P-
dCTP. The primers used for amplification of consensus spliced MEFV
were anchored in exon 2 and exon 5 (top); the expected 672-bp product
is indicated, along with an additional larger product (asterisk). B, The
primers used for amplification of exon 2 transcripts were anchored at the
junction of exons 1/3 and in exon 5; the expected 543-bp product is
indicated in the autoradiograph, along with an additional larger product
(asterisk). C, Ribonuclease protection assays. Left, A 493-bp probe
containing sequences from exons 1 and 2 was used to generate a protected
fragment of 493 bp from consensus spliced MEFV (Exon 12), and a
fragment of 276 bp from exon 2 transcripts. Right, Autoradiographs of
the resolved products. See Figure 1 for other definitions.
Figure 4. Identification of alternatively spliced MEFV transcripts
containing exons 4a and 2a. A, Exon 4a. The sequence of exon 4a is
shown in boldface, flanked by exons 4 and 5. Underlined is the first of
a series of generated 3 stop codons. A diagrammatic representation of
the MEFV gene is also shown, with exon 4a represented as a black box
nested inside intron 4. The generation of the exon 4a protein product
and a second product that contains exon 4a but lacks exon 2 (exon
2/4a) is also diagrammed. B, Exon 2a. The sequence of exon 2a is
shown in boldface, flanked by exons 1 and 3. A diagrammatic
representation of the MEFV gene is also shown, with exon 2a
represented as a black box nested in intron 2. Diagrams of detected
alternative splicing events and their resulting protein products, includ-
ing those containing exon 8ext and exon2a (Exon 2a/8ext) and
transcripts containing exon 8ext but not exon 2 (Exon 2/8ext), are
also shown.
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firmed that exon 2 transcripts were at least 2 orders of
magnitude less abundant than transcripts containing
exon 2 (results not shown).
We also investigated whether transcripts contain-
ing combined splicing events at exon 2 and exon 8 were
expressed in synovial fibroblasts and PBLs. Specific
primers were designed to detect each isoform individu-
ally. Although both cell types produced all 4 possible
transcripts (consensus, exon 8ext, 2, and 2/8ext), the
latter form was exceedingly rare. A figure depicting these
results is available online at http://www.med.umich.edu/
cdb/sub_pages/People/gumucio.htm.
Identification of exon 4a. During analysis of exon
2 isoforms, we detected a larger product (asterisk in
Figures 3A and B). Sequencing showed that this product
contained an extra 98 bp following exon 4, corresponding
to a small exon nested in intron 4; hence, it was named
Figure 5. Summary of the alternative splice forms of MEFV tran-
scripts in synovial fibroblasts and peripheral blood leukocytes. Hori-
zontal bars represent spliced transcripts, named on the left. The coding
exons are numbered. The predicted molecular weights of the predicted
translated products (kilodaltons) are on the right. FL  full-length.
A B
Figure 6. Subcellular localization of recombinant pyrin isoforms and native pyrin. A, Synovial fibroblasts were transiently transfected with plasmids
encoding myc-tagged full-length pyrin (FL) or pyrin isoforms lacking exon 2 (2) or containing exon 2a, and processed as described in Materials and
Methods. Pyrin protein was detected in transfected cells with an anti-myc antibody and visualized in the rhodamine channel (red; left column), nuclei
were counterstained with 4,6-diamidino-2-phenylindole (DAPI) (blue; middle column), and the images were merged (right column). The 3 patterns
of subcellular localization detected for exon 2 protein are shown in the center 3 bracketed rows as cytoplasmic (top), predominantly nuclear
(middle), and mixed cytosolic/nuclear (bottom). B, Native pyrin was detected with a polyclonal antipyrin primary antibody and an Alexa Fluor 568
rhodamine–conjugated secondary antibody (red). Nuclei were counterstained with DAPI or Hoechst stain (blue). a and b, Specificity of the antibody
is verified in HeLa cells transfected with myc-pyrin and visualized with a, the antipyrin antibody (red) or b, an anti-myc monoclonal antibody (green).
A nontransfected cell is indicated by the arrowhead. c–e, Native pyrin in synovial fibroblasts: c, pyrin, d, merged image of pyrin and DAPI stain, e,
dual-channel image of the nuclei obtained by confocal microscopy. f–h, Native pyrin in DCs: f, pyrin, g, merged image of pyrin and Hoechst stain,
h, dual-channel confocal image of the nuclei. i–j, Native pyrin in polymorphonuclear cells (PMN): I, pyrin, j, Hoechst stain, k, merged image of pyrin,
Hoechst, and differential interference contrast. l–m, Sequential confocal slices through a monocyte (Mo), moving from l, the top of the cell to n,
the bottom, showing cytoplasmic reticular staining of pyrin (red). See Figure 1 for other definitions.
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exon 4a. Exon 4a is in-frame with exon 4. However, its
insertion causes a frameshift at the beginning of exon 5 that
results in multiple stop codons (Figure 4A). The predicted
product is a 490–amino acid truncated protein lacking
exons 5–10, thus missing much of the coiled-coil and the
entire rfp/SPRY/B30.2 domain (see Figure 1C). Tran-
scripts containing exon 4a are in low abundance in PBLs
and are barely detectable in synovial fibroblasts.
Identification of exon 2a. While sequencing RT-
PCR products with combined splicing events, we de-
tected clones containing a small sequence substituting
for exon 2. Analysis revealed this to be a 93-bp sequence
embedded in intron 2, referred to here as exon 2a. Exon
2a is in-frame, and therefore is likely to result in a
full-length translated protein (Figure 4B) with an alter-
native exon 2. These transcripts are extremely rare (data
not shown).
Summary of alternatively spliced MEFV tran-
scripts. Overall, in the present study we identified 3 new
splice isoforms of MEFV mRNA in synovial fibroblasts
and PBLs (exon 2a, exon 4a, and exon 8ext) and
confirmed the presence of the previously identified exon
2. We have also demonstrated the existence of tran-
scripts containing combined splicing events, resulting in
a total of 9 different MEFV transcripts (Figure 5).
Subcellular localization of recombinant pyrin
isoforms. To determine the subcellular localization of
the protein products encoded by the various alterna-
tively spliced MEFV transcripts, we performed transient
transfections of synovial fibroblasts and HeLa cells, with
expression plasmids encoding the myc-tagged pyrin iso-
forms represented in Figure 5. All protein products
encoded by sequences containing exon 2 or exon 2a had
a cytoplasmic localization, regardless of whether they
contained, at the 3 end, a consensus splicing (Figure
6A), an exon 8ext, or an exon 4a (figure available at
http://www.med.umich.edu/cdb/sub_pages/People/
gumucio.htm). Protein products encoded by exon 2
forms had cytoplasmic, nuclear, or mixed (nuclear and
cytoplasmic) localization, regardless of whether they
contained, at the 3 end, a consensus splicing (Figure
6A), an exon 8ext, or an exon 4a (figure available at
http://www.med.umich.edu/cdb/sub_pages/People/
gumucio.htm). The same findings were observed in
HeLa cells (results not shown).
We determined the frequency of each localiza-
tion pattern for each pyrin isoform by counting 50–100
transfected cells. This analysis showed that cells trans-
fected with plasmids encoding exon 2 proteins more
frequently exhibited a mixed localization (average 67%),
followed by cytoplasmic localization (average 25%), and
less frequently, an exclusively nuclear localization (aver-
age 8%). All other isoforms were 100% cytoplasmic
(table available at http://www.med.umich.edu/cdb/
sub_pages/People/gumucio.htm).
Subcellular localization of native pyrin. The
transcript analysis and transfection experiments indi-
cated that the majority of pyrin protein should be
cytoplasmic in synovial fibroblasts as well as PBLs. To
test this, we examined a variety of relevant human cell
types using an antibody to detect native human pyrin. To
confirm the specificity of the antibody, HeLa cells were
transfected with myc-pyrin and stained with antipyrin
antibody or anti-myc antibody; only transfected cells
showed cytoplasmic staining with both antibodies (Fig-
ures 6Ba and Bb). Unexpectedly, untreated and LPS-
treated synovial fibroblasts stained with antipyrin dis-
played a predominantly nuclear localization (apparently
excluding the nucleolus), with some cytoplasmic staining
(Figures 6Bc–e). In widefield surveys, all cells showed
identical staining (results not shown). In immature
monocyte–derived DC, pyrin presented predominantly
as intranuclear clusters (Figures 6Bf–h). PMNs also
showed predominantly nuclear staining (Figures 6Bi–k);
only in monocytes was pyrin predominantly cytosolic
(Figures 6Bl–n), and distributed in a reticular pattern.
DISCUSSION
Most inflammatory episodes in FMF are charac-
terized by massive influx of PMNs to peritoneal, pleural,
or synovial membranes. The reason for the targeting of
PMNs to these particular sites is not known, but it is
possible that local expression of pyrin protein could be
involved. Thus, it was important to define whether
resident cells in the tissues targeted for inflammation in
FMF express MEFV. In the present study, we investi-
gated resident cells from joint tissues and demonstrated
that MEFV transcripts and pyrin protein are expressed in
synovial fibroblasts (and in dendritic cells), but not in
chondrocytes and endothelial cells. The potential of
contaminating inflammatory cells being the source of
MEFV transcripts in synovial fibroblast cultures was
minimized by using synovial fibroblasts from passages
4–10. Moreover, we confirmed that all cells in the
culture exhibited typical fibroblastic morphology and
pyrin staining.
Although the level of MEFV transcripts in syno-
vial fibroblasts was lower compared with that seen in
unfractionated PBLs, MEFV message was consistently
up-regulated by treatment with LPS, as has been shown
in PBLs (13,14,20). Synovial fibroblasts are biologically
3686 DIAZ ET AL
active cells with potential for cytokine and chemokine
production; this may allow them to actively participate in
the inflammatory process in FMF. Conversely, pyrin
expression by synovial fibroblasts may also modulate
other inflammatory conditions. Indeed, in a Turkish
cohort of patients with juvenile idiopathic arthritis, it
was found that the carrier frequency of the M694V allele
was significantly higher than in the general population
(28). This strong association suggests that pyrin function
may affect the expression of chronic idiopathic arthrop-
athies.
Herein we describe 2 previously unrecognized
alternative splicing events, involving exon 4a and exon
8ext, that produce frameshifts and predict truncated
protein products lacking exons 5–10 and exons 9 and 10,
respectively. The exon 8ext transcript is of particular
interest since it accounts for up to 27% of the synovial
fibroblast transcripts. This transcript encodes a protein
similar in structure to native mouse and rat pyrin, which
also lack exon 10 (29). This exon encodes the rfp/B30.2/
SPRY domain that is predicted to function in ligand
binding or signal transduction (30). The localization of
the majority of human FMF mutations to this exon
suggests that it encodes a critical part of the molecule.
Thus, it is curious that all mouse and rat forms, as well
as some human forms of pyrin, lack the domain encoded
by this exon. One possibility is that this domain imparts
a regulatory function that modulates some basal prop-
erty of the rest of the pyrin molecule. In this context, it
is notable that one FMF mutation (Y668X) encodes a
frameshift that results in the loss of half of the rfp
domain (31). It is not yet clear whether this partial
deletion completely abrogates the function of the rfp
domain, but if so, this “natural” model would predict
that the basal activity of the rest of the pyrin molecule
(and perhaps by extension, that of the exon 8ext protein
product) is proinflammatory.
The protein product of the exon 4a transcript
resembles the truncated form of pyrin engineered in the
context of a mouse model of FMF containing exons 1, 2,
and part of exon 3; these mice exhibit a proinflammatory
phenotype, with increased IL-1 production and im-
paired apoptosis (32). Although the exon 4a product is
present at very low concentrations, it will be important
to learn whether its function resembles that of the
truncated mouse form. If so, this product could poten-
tially modulate pro–caspase 1 activation and IL-1
production, as well as apoptosis (32).
Synovial cells also express two MEFV splice
forms that involve exon 2: one lacking exon 2 (2) and
one in which a small exon is substituted for the canonical
exon 2 (2a). Interestingly, comparison of MEFV exon 2
in humans and rodents indicates that this is a particularly
poorly conserved region of the pyrin protein (29); thus,
this region of the pyrin protein may not be under major
functional constraints. The exon 2 splice form was
identified in previous studies and shown to encode a
protein product that localizes to the nucleus (27). In our
transfection studies, this transcript was the only isoform
to encode a nuclear form of pyrin protein. Importantly,
proteins encoded by exon 2 were not exclusively nu-
clear and were more often cytoplasmic, suggesting that
they may shuttle between these two environments. How-
ever, the exon 2 (and exon 2a) transcripts were ex-
pressed at such low levels in LPS-stimulated synovial
fibroblasts and PBLs that their functional significance is
unclear. It seems highly unlikely that the rare exon 2
nuclear form could account for the native nuclear pyrin
protein observed in several cell types, although an
unusually stable mRNA or protein could potentially play
some role.
The expression of these pyrin protein isoforms
also has the potential to affect interactions between
pyrin and other proteins. Thus far, pyrin has been shown
to interact with 2 proteins, ASC (33) and PSTPIP1/
CD2BP1 (19). ASC is involved in NF-B activation,
caspase 1 activation, and apoptosis, and there are data
suggesting that pyrin can modulate each of these func-
tions (32–35). The interaction between pyrin and ASC is
mediated by exon 1, the region that encodes the death
domain–related pyrin domain of both proteins. Since all
splice isoforms identified retain exon 1, all encoded
protein forms should retain the ability to interact with
ASC, although it is possible that the outcome of this
interaction may be different, especially when the trun-
cated forms (4a and exon 8ext) are involved.
The PSTPIP1–pyrin interaction involves the re-
gion of pyrin encoded by exons 3–8 (B box and coiled-
coil), and could therefore be compromised in the case of
the exon 4a form, or altered in affinity or function in the
case of the exon 8ext form. Recently, it was demon-
strated that PSTPIP1 is mutated in PAPA syndrome (9)
and that the 2 major PSTPIP1 mutations functionally
affect IL-1 processing and also increase the interaction
between pyrin and PSTPIP1 (19). This suggests that
these 2 proteins lie in the same inflammatory pathway.
Further analysis of possible differences in interaction or
functional modulation of these pathways imparted by
the different protein isoforms of pyrin is an important
future goal since preferential expression of some poten-
tially proinflammatory isoforms may result in the FMF
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phenotype in patients with no identified MEFV muta-
tions, or may contribute to the inflammatory state in
other conditions.
Finally, we have established in this study that
native pyrin protein is localized in different subcellular
compartments in different cell types. Nuclear localiza-
tion in synovial fibroblasts, DCs, and PMNs was unex-
pected since the majority of MEFV transcripts found in
all of these cell types are full length, and studies of
recombinant pyrin in transfected cells, including those
described here, have consistently indicated that full-
length pyrin is cytoplasmic (27,32,33,36,37). Nuclear
localization in synovial fibroblasts was not due to LPS
exposure since unstimulated cells also displayed nuclear
pyrin. It is likely that mechanisms besides alternative
splicing, such as cell-specific posttranslational processing
and/or protein–protein interactions, may ultimately de-
termine subcellular localization. The existence of various
pyrin isoforms with potentially pro- and antiinflamma-
tory functions, and the observation that native pyrin has
a different subcellular localization depending on cell
type, indicate that the role of pyrin in the inflammatory
process is highly complex and context-specific.
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